Noticias de KOD_US

Mercado

Noticias del mercado

Últimas noticias sobre KOD_US — 235 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: KOD_US ✕ 235 resultados
28/09/2026 KOD_US — Ophthalmology Times
DAYBREAK: Tarcocimab, tabirafusp-ted noninferior to aflibercept in wet AMD | Eye Care Network - Modern Retina

Tarcocimab, tabirafusp-ted were noninferior to aflibercept in DAYBREAK wet AMD trial; 54% on tarcocimab reached 24-week dosing.

28/09/2026 KOD_US — Timothy Sykes
KOD Stock Jumps As Phase 3 Retina Catalysts Approach

Kodiak Sciences Inc soars as pivotal clinical trial success fuels optimism, and stocks have been trading up by 87.2 percent. Key Takeaways UBS reiterates a Buy on Kodiak Sciences, tying an $80 price target to upcoming Phase 3 wet AMD data for tarcocimab and KSI-501 versus Eylea, well above the

28/09/2026 KOD_US — Timothy Sykes
KOD Stock Jumps As Phase 3 Data Catalyst Looms

Kodiak Sciences Inc surged as stocks have been trading up by 69.18 percent following highly positive clinical trial news Key Takeaways UBS reiterates a Buy on Kodiak Sciences with an $80 price target versus the current roughly $31 KOD share price, pointing to major upside if key trials deliver.

25/09/2026 KOD_US — Yahoo Finance
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration

Kodiak Sciences Inc. (Nasdaq: KOD), una empresa de biotecnología precomercial centrada en la retina comprometida con la investigación, el desarrollo y la comercialización de terapias transformadoras, anunció hoy que la compañía informará los resultados principales de DAYBREAK, un estudio de fase 3 que evalúa tanto Zenkuda TM (tarcocimab tedromer) como KSI-501 (tabirafusp alfa tedromer) para el tratamiento de pacientes con degeneración macular húmeda relacionada con la edad, el lunes. 28 de septiembre de 2026.

25/09/2026 KOD_US — Stock Titan
Results are due Monday from a study of two potential treatments for an age-related eye disease.

Kodiak's DAYBREAK study evaluates Zenkuda and KSI-501 for wet age-related macular degeneration; topline results are scheduled for webcast at 8:30 a.m. ET.

Página 11 de 12